Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00594945 · ClinicalTrials.gov registry record · Phase 2
Study of Intranasal Clonazepam in Adult Subjects With Epileptic Seizures
A Phase 2 study of Epilepsy, sponsored by Jazz Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 45
- Enrollment target
- 6
- Study locations
NCT00594945: Completed Phase 2 study of Epilepsy, sponsored by Jazz Pharmaceuticals.
NCT00594945 is a Phase 2 study of Epilepsy that has completed, run by Jazz Pharmaceuticals. The registered enrollment target is 45 participants, below the 952-participant average among 160 other Epilepsy trials with a reported enrollment target (95% lower). The trial reports 6 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00594945, a Phase 2 study of Epilepsy, has completed, sponsored by Jazz Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 45 participants
- Enrollment target
- 6
- Study locations
Study Summary
Evaluate the safety and efficacy of intranasal Clonazepam in subjects with epilepsy.
Primary Outcome
Summary of video EEG number of spikes and sharp waves. Over a 24 hour period.
Conditions Studied
Interventions
- DRUG Clonazepam
Study Locations (6)
Arkansas
- Clinical Trials. inc. - Little Rock
Maryland
- Mid-Atlantic Epilepsy & Sleep Center - Bethesda
New York
- Columbia Comprehensive Epilepsy Center, Neurological Institute - New York
Ohio
- Ohio State University - Columbus
Texas
- Neurological Clinic of Texas, PA - Dallas
Other
- Tampere University Hospital - Tampere
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2007-12 |
| Est. Completion | 2009-06 |
| Phase | Phase 2 |
What the finished NCT00594945 record still lists
NCT00594945 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 952-participant average among 160 other Epilepsy trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Epilepsy appearing as the primary indexed condition, and to 1 intervention - of which Clonazepam is the first listed.
NCT00594945 lists 6 locations in 6 states (Arkansas, Maryland, New York).
Frequently Asked Questions
What is clinical trial NCT00594945 about?
NCT00594945 is a clinical study titled "Study of Intranasal Clonazepam in Adult Subjects With Epileptic Seizures". Evaluate the safety and efficacy of intranasal Clonazepam in subjects with epilepsy.
What is the current status of trial NCT00594945?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 45 participants. The study started on 2007-12. Estimated completion is 2009-06.
What conditions does trial NCT00594945 study?
This clinical trial studies the following conditions: Epilepsy.
What interventions are being tested in trial NCT00594945?
The interventions under investigation include: Clonazepam (DRUG).
Who is sponsoring clinical trial NCT00594945?
This trial is sponsored by Jazz Pharmaceuticals, which has 128 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00594945 being conducted?
This trial has 6 study locations across Arkansas, Maryland, New York, Ohio, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Epilepsy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00594945's enrollment target sits among peer trials
45 90th of 160 higher than 71 of 160 other Epilepsy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Epilepsy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention Study
RECRUITING · Phase 2
-
A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures
RECRUITING · Phase 2
-
RNS System LGS Feasibility Study
ACTIVE NOT RECRUITING · Phase 2
-
Study of an External Responsive Neurostimulator System on Epileptiform Activity
COMPLETED · Phase 2
-
Abnormal Ventilatory Response to Carbon Dioxide: a Potential Biomarker for Seizure Induced Respiratory Depression & Modification by SSRI
COMPLETED · Phase 2
-
Hormone Replacement in Menopausal Women With Epilepsy
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia